Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reply to private message.
Thank you. Your point makes perfect sense.
Shout out to NNVCBob;
I believe you've previously posted Shelton progress photos. Do you have any new images to share?
I can't envision a scenario where NanoViricides changes priorities from FluCide to DengueCide.
I can envision a long-shot scenario where DengueCide is licensed to another Pharma, where testing is funded by that Pharma and due to Orphan Designation and absence of any alternative Dengue cure special use approval is granted earlier than FluCide.
There are companies like BVGH that specialize in Orphan Drugs and that have significant internal resources primed and well connected to secure Government and NGO funding. BVGH could more rapidly and efficiently gain approval and distribution of an effective dengue cure then NNV could on its own. BVGH needs source technology for its survival and well being. BVGH has more capability implementing Orphan drugs then originating same. A match made in heaven.
A milestone day. This event can play out in many ways. The voucher's value, if secured, is a big plus. It can serve simply, as has been stated, as a cashflow instrument, it could accelerate FluCide when US Approval draws near and it could be an enticing bonus to a Big Pharma interested in a license agreement.
You were on a roll the for a stretch. Too much coffee?
Glad you got your additional 10k. I think you, we, are in the right place. ECTE is going to climb with study results and certification.
Improved glucose results are great for patients. But...reduced hospital litigation risk and insurance rates will be great for ECTE's bottomline.
I agree, the appointment will go largely unnoticed by the market. Still the move is significant and like others announced in the past 12 months, strategically important. Nanoviricides is no one trick pony and effort continues on cures for Herpes of the eye along with other life threatening disease.
Congratulations to Dr. Boniuk and us, the shareholders.
A good back of the napkin sketch. Virus families differ and various strains within a viral family benefit by tuning of the viricide to optimize efficacy against particular virus.
The first viricide to achieve industry, medical, government, or FDA approval will validate Nanoviricides' technology and the potential of their revolutionary drug platform.
Toxicity testing is a known. Nanoviricides is producing to meet the known need. If an opportunity to test against H7N9, in UK or Canada, arises an evaluation of strategic value versus tactical disruption should be undertaken.
No SARS testing at this time. The focus is on FluCide Tox. Material manufacture is focused on influenza. SARS testing requires primates. Primates would require too great a quantity of viricide at a time when every bit produced is designed and intended for FluCide Tox.
Focus.
The conservative view, no deals done until phase 3 is complete. Yet Bind has done 3 deals with potential value $1 billion. Time will tell.
Nanoviricides has cash on hand for Shelton, Toxicity and Phase 1. There will be PRs while the strategic initiatives are fulfilled. Nanoviricides is not standing still, with FluCide and other drug research, while the three keys above play out. PPS will float up and down based on PRs. Tox, Phase 1 and deal interest will turn the trend upward. Investors, with time, will see large profits. Speculators will come and go. Some with gains and some losses. I wish GLT those who contribute honestly to the exchange of ideas.
A verbal sucker punch. No class.
Thank you. The article dates back to the very earliest days of my investment in Nanoviricides before I started saving PR's and supporting articles.
Does anyone know of published academic papers resulting from Dr. Kasoules' studies?
If anyone on the board has a link to papers or news articles related to Dr. Kasoules research please post. The only reference to his work resulting from a Google search turns up post after post from a familiar poster. Quite frankly the take away is a disincentive to investors and disquieting for the lack of fulfillment of promise.
A combination of a flushing agent and HIVCide is the ideal combo.
I was adding to your point not contradicting or correcting.
UK testing need not be exclusive. There is nothing preventing or prohibiting Canadian testing. Don't assume because Canada has not be called out yet it won't play a part down the road.
Acknowledged. My error.
More Lawfirms then disgruntled investors. Time for an Ambulance Chaser cage match. They're so pathetic I almost feel sorry for them...almost.
FluCide efficacy has been repeatedly confirmed in animals.
You may want to tune your radio. There have been a number of incremental science, operational and business announcements in the year since Pre-IND. I see steady progress. It is true that Nanoviricides is making progress. The pace works for some and most certainly is unacceptable to others who post here.
Einstein: "Put your hand on a hot stove for a minute and it seems like an hour. Sit with a pretty girl for an hour, and it seems like a minute."
If you follow the technology closely, no the news is not explicitly "new". But Nanoviricides is new to many in the Medical Profession and to many investors and while H7N9 is in the news Nanoviricides should draft.
With all concern and hope for a quick resolution to the latest outbreak and with respect to those impacted by infection and illness, Nanoviricides should take this opportunity to educate the world to their potential life saving drugs.
The nano-pharm space is growing more "crowded". When Dr. Diwan first proposed his innovative solution he was dismissed as a nobody. "Why he doesn't even have a peer reviewed publication to his name." I grow more confident with each publication validating the safety and practicality of technologies similar in concept to Nanoviricides. Patent overlap/infringement may become an issue but for now I find strength in the growing number of nano medical pioneers gaining acceptance and increasing awareness.
Vile-vial. Haa! Good stuff.
DNA markers used throughout the manufacturing and distribution process are needed to protect consumers and honest pharm from those willing to trade integrity for a dollar.
Tests were conducted on the pigs. No evidence of H7N9. In fact there were indication of cause other then influenza. The article was explicit on this subject.
Tests were conducted on the pigs. No evidence of H7N9. In fact there were indication of cause other then influenza. The article was explicit on this subject.
You are correct up to a point. Nanoviricides is most certainly a developing versus production bio nano-pharm. Nanoviricides is two years from product-generated revenue. (Licensing revenue is another story and not one easily predicted.)
But...Outbreaks do generate interest and do in turn have an inflationary impact on PPS. The threat of pandemic outbreak and resulting impacts on economies speeds the regulatory pipeline and can influence grant and orphan funding for endemic illnesses with potential geo creep or pandemic mutability.
Nanoviricides and others in the anti viral research space do not exist in a vacuum. Events in the real world impact the potential value of developing technologies.
Hype is an intangible that has made millionaires.
I agree, inappropriate.
Your statement is insulting, by the global nature of the slur and supremely ironic. I trust Applied DNA Sciences to make an informed decision regarding the security of their technology before entering into a partnership in China, the US or with any global partner.
Please clarify, Dengue is not transmitted human to human?
A good article on Patent distribution.
http://www.renewoureconomy.org/sites/all/themes/pnae/patent-pending.pdf
Thanks for your reply. Your point is accurate, Patent awards are granted to foreign born residents in the majority of instances. I maintain that they study and conduct research at US Universities and do creative work for US companies because the US nurtures and rewards innovation. The world has sent her best to our shores because we offer opportunity to create and invent. It has been so for 400 years. Will it be so forever? Will another nation take our place? Nothing lasts for ever but I don't see the world beating a path to China, India or Brazil just yet.
Some facts before we start planning the End of American Innovation party.
http://www.uspto.gov/web/offices/ac/ido/oeip/taf/cst_all.htm
Viricides don't catch so much as get caught. Virus are looking for the binding properties that viricides mimic. A cloaked virus may hide from the immune system, in similar fashion to our viricides, but it seeks out the binding characteristics so well designed by Dr. Diwan. The "invisible" virus seeks out the readily available virus-specific viricides in the bloodstream.
The article is informative as a recipe for how to avoid immune system interaction.
Cox' article is reassuring at a contentious time. The market response and shorts response will be interesting. I am averaging down. Question is, how far down will we go?
In answer to a question regarding Dr. Diwan's reception at today's seminar jointly hosted by the Center for Biological Physics and the California NanoSystems Institute and whether the presentation will be available to the public Dr. Seymour replies:
...Extremely well received with people from Physics, BioPhysics, Chemistry, BioChemistry and Biology in the room. They threw him all kinds of questions that he answered quite well.
A video of the presentation should be up on the UCLA NanoSystems website next week. As soon as I have more info, we will make it public with a formal press release.
Sincerely,
EUGENE SEYMOUR, MD, MPH
Chief Executive Officer
NANOVIRICIDES, INC
Thank you. Great paper. One of the better characterizations of viral mutation and the resulting challenge to drugs designed to interrupt viral reproductive cycles.
http://www.scripps.edu/strosberg/documents/2009_wei_new.pdf
Similar indoline alkaloid-type compounds anti-viral findings for Hep C in 2009. The potential for broad range anti-viral treatment is encouraging as a potential treatment. I've read references to similar inhibiting action as earlier, 2007-8, but I've not seen any push toward commercialization. Does anyone recognize the technology in drugs heading to trials or to market?
California NanoSystems Institute: the setting for tomorrow's presentation.
http://www1.cnsi.ucla.edu/staticpages/about-us